Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ipsen S.A. (OTC: IPSEF).

Full DD Report for IPSEF

You must become a subscriber to view this report.


Recent News from (OTC: IPSEF)

Exelixis and Ipsen initiate COSMIC-312 trial in advanced HCC
Exelixis (NASDAQ: EXEL ) and Ipsen ( OTCPK:IPSEF ) has initiated COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). More news on: Exelixis, Inc., Ip...
Source: SeekingAlpha
Date: December, 05 2018 06:06
European Commission OKs Exelixis and Ipsen's Cabometyx for second-line liver cancer
Exelixis (NASDAQ: EXEL ) announces that collaboration partner Ipsen ( OTCPK:IPSEF ) has received marketing approval from the European Commission for CABOMETYX (cabozantinib) as monotherapy in adult patients with hepatocellular carcinoma who have been previously treated with Bayer's Nexavar...
Source: SeekingAlpha
Date: November, 15 2018 07:21
Key events next week - healthcare
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 12 2018 08:52
Ipsen Canada Appoints Ed Dybka as General Manager
Ipsen Canada Appoints Ed Dybka as General Manager Canada NewsWire MISSISSAUGA, ON, Oct. 11, 2018 MISSISSAUGA, ON , Oct. 11, 2018 /CNW/ - Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dy...
Source: Canada Newswire
Date: October, 11 2018 08:00
Exelixis' partner Ipsen announces positive CHMP opinion for CABOMETYX tablets
Exelixis (NASDAQ: EXEL ) announces that its partner Ipsen ( OTCPK:IPSEF ) received a positive opinion from the CHMP, for CABOMETYX (cabozantinib) tablets as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. More n...
Source: SeekingAlpha
Date: September, 21 2018 06:45
Ipsen S.A. ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Ipsen S.A. ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: July, 26 2018 13:52
Ipsen and Biolabs to open new innovation center in Cambridge (U.S.)
Ipsen ( OTCPK:IPSEF ) and BioLabs to open a life science co-working facility called the ‘Ipsen Innovation Center - BioLabs’ (IPSEN-ICB) within the company’s new North America global hub in Kendall Square, Cambridge, Massachusetts, to foster development of new ther...
Source: SeekingAlpha
Date: July, 19 2018 07:20
Crinetics Pharmaceuticals Readies $80 Million IPO
Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise $80 million from the sale of its common stock in a U.S. IPO, according to an amended registration statement . The company is developing a pipeline of treatment candidates for rare endocrine disorders. CRNX has achieved pro...
Source: SeekingAlpha
Date: July, 10 2018 13:27
Crinetics Pharmaceuticals Begins IPO Process
Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . Crinetics is a clinical-stage pharmaceutical company that develops and manufactures pharmaceuticals for endocrine diseases and en...
Source: SeekingAlpha
Date: June, 28 2018 10:36
Cabometyx approved in Europe for first-line kidney cancer; Exelixis up 5% premarket
Exelixis (NASDAQ: EXEL ) is up  5%  premarket, albeit on only 100 shares, in response to its announcement that the European Commission has approved commercialization partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application for CABOMETYX (cabozantinib) for the first-li...
Source: SeekingAlpha
Date: May, 17 2018 07:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A141.7512N/AN/A0
2018-12-13N/A141.7512N/AN/A0
2018-12-12N/A141.7512N/AN/A30
2018-12-11N/A141.7512N/AN/A0
2018-12-10N/A141.7512N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-19100100100.0000Short
2018-04-041616100.0000Short
2018-02-27121121100.0000Short
2017-09-21300300100.0000Short
2017-08-18343343100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IPSEF.


About Ipsen S.A. (OTC: IPSEF)

Logo for Ipsen S.A. (OTC: IPSEF)

Ipsen is a global specialty driven pharmaceutical company with total sales exceeding . billion in . Ipsen s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro oncology. Moreover, the Group has an active policy of partnerships. R amp D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In , R amp D expenditure totaled close to million, representing more than of Group sales. The Group has total worldwide staff of close to , employees.

 

Contact Information

 

 

Current Management

  • JeanLuc Belingard / CEO
  • Caire Giraut / EVP, CFO
  • JeanLuc Belingard / Chairman

Current Share Structure

  • Market Cap: $12,279,723,606 - 03/12/2018
  • Issue and Outstanding: 84,223,070 - 10/07/2011

 



Daily Technical Chart for (OTC: IPSEF)

Daily Technical Chart for (OTC: IPSEF)


Stay tuned for daily updates and more on (OTC: IPSEF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IPSEF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IPSEF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IPSEF and does not buy, sell, or trade any shares of IPSEF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/